Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Miltenyi Biomedicine GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNICANCER
OHSU Knight Cancer Institute
Northwestern University
University of Texas Southwestern Medical Center
Dana-Farber Cancer Institute
University of South Florida
Shandong Cancer Hospital and Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)